XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet‐induced obesity. Issue 3 (29th October 2012)

• Record Type: Journal Article
• Authors: Bhaskar, V.; Lau, A.; Goldfine, I. D.; Narasimha, A. J.; Gross, L. M.; Wong, S.; Cheung, B.; White, M. L.; Corbin, J. A.
• Is Part Of: Diabetes, obesity & metabolism. Volume 15:Issue 3(2013:Mar.)
• Page Start: 272
• Page End: 275
• Publication Date: 2012-10-29
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12019
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>XMetA, a high‐affinity, fully human monoclonal antibody, allosterically binds to and activates the insulin receptor (INSR). Previously, we found that XMetA normalized fasting glucose and glucose tolerance in insulinopenic mice. To determine whether XMetA is also beneficial for reducing hyperglycaemia due to the insulin resistance of obesity, we have now evaluated XMetA in hyperinsulinemic mice with diet‐induced obesity. XMetA treatment of these mice normalized fasting glucose for 4 weeks without contributing to weight gain. XMetA also corrected glucose tolerance and improved non‐high density lipoprotein cholesterol. These studies indicate, therefore, that monoclonal antibodies that allosterically activate the INSR, such as XMetA, have the potential to be novel agents for the treatment of hyperglycaemia in conditions associated with the insulin resistance of obesity.</p> </abstract>